Hatter Horizon Series 2018: Multimedia
Monday 10th December 2018
Videos of the presentations will be posted where when available.
Reducing the global burden of diabetes & cardiovascular disease: is there a role for governments?
Professor Dinky Levitt
University of Cape Town, South Africa
How will genetics impact on prevention and treatment of type 2 diabetes?
Professor Mark McCarthy
Oxford Centre for Diabetes, University of Oxford, UK
The biology and therapeutic potential of SGLT2 inhibition - another year on!
Professor Nikolaus Marx
University of Aachen, Germany
SGLT2 Outcome trials - an evolving story
Professor Stephen Wiviott
Brigham & Women's Hospital, Boston, USA
Do GLP-1 analogues and SGLT2 inhibitors have a role beyond type 2 diabetes - i.e. weight management?
Professor Melanie Davies
Diabetes Research Centre, University of Leicester, UK
Is it time to rethink HbA1c?
Dr Dev Singh
New Cross Hospital, Wolverhampton, UK
How do SGLT2 inhibitors benefit the kidney?
Professor David Wheeler
University College London
Is there still a place for sulphonylureas?
Professor Cliff Bailey
Aston University, Birmingham, UK